IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Sold by Federated Hermes Inc.

Federated Hermes Inc. trimmed its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 5.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,767,926 shares of the company's stock after selling 295,600 shares during the period. Federated Hermes Inc. owned approximately 5.44% of IDEAYA Biosciences worth $78,099,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of IDYA. Janus Henderson Group PLC raised its position in IDEAYA Biosciences by 13.5% during the fourth quarter. Janus Henderson Group PLC now owns 5,857,639 shares of the company's stock worth $150,606,000 after acquiring an additional 695,263 shares during the period. Norges Bank acquired a new position in IDEAYA Biosciences during the fourth quarter worth $13,385,000. MPM Bioimpact LLC acquired a new position in IDEAYA Biosciences during the fourth quarter worth $10,641,000. FMR LLC raised its position in IDEAYA Biosciences by 2.6% during the fourth quarter. FMR LLC now owns 12,963,151 shares of the company's stock worth $333,153,000 after acquiring an additional 327,498 shares during the period. Finally, Vanguard Group Inc. raised its position in IDEAYA Biosciences by 5.9% during the fourth quarter. Vanguard Group Inc. now owns 5,078,084 shares of the company's stock worth $130,507,000 after acquiring an additional 282,936 shares during the period. 98.29% of the stock is currently owned by institutional investors and hedge funds.

IDEAYA Biosciences Price Performance

Shares of IDYA traded down $0.08 during mid-day trading on Friday, reaching $24.27. The stock had a trading volume of 860,814 shares, compared to its average volume of 1,160,613. The firm has a market cap of $2.13 billion, a price-to-earnings ratio of -6.76 and a beta of 0.03. The business's fifty day moving average is $21.96 and its 200 day moving average is $20.34. IDEAYA Biosciences, Inc. has a 52-week low of $13.45 and a 52-week high of $41.08.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same period in the prior year, the firm earned ($0.53) EPS. As a group, sell-side analysts anticipate that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on IDYA. Royal Bank Of Canada raised shares of IDEAYA Biosciences from an "outperform" rating to a "moderate buy" rating and dropped their target price for the stock from $57.00 to $30.00 in a report on Wednesday, July 9th. TD Cowen began coverage on shares of IDEAYA Biosciences in a report on Tuesday, July 22nd. They set a "buy" rating for the company. Wells Fargo & Company began coverage on shares of IDEAYA Biosciences in a report on Thursday, June 26th. They set an "overweight" rating and a $44.00 target price for the company. The Goldman Sachs Group raised shares of IDEAYA Biosciences to a "hold" rating and set a $25.00 target price for the company in a report on Thursday, July 10th. Finally, JPMorgan Chase & Co. upped their target price on shares of IDEAYA Biosciences from $66.00 to $72.00 and gave the stock an "overweight" rating in a report on Monday. Three investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $48.09.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.